Oyster Therapeutics, formerly Kesmalea, has raised $60 million to advance a protein degradation platform designed to overcome the size constraints of the blood-brain barrier. Rather than delivering a complete bifunctional degrader, the molecules cross as smaller fragments and self-assemble into the active complex once inside the brain, with tau as the lead target. Clearing pathological tau addresses one of the central accumulations implicated in neurodegeneration and cognitive decline.
Key Points
- London's Oyster raises $60m for brain-penetrant protein degradation platform
- Degrader fragments cross blood-brain barrier, then self-assemble intracellularly
- Tau is the lead target in neurodegenerative protein accumulation
Longevity Analysis
Neurodegeneration is fundamentally a failure of cellular waste removal — proteins that should be tagged and dismantled instead accumulate and interfere with the signalling architecture of the brain. Pharmacological approaches that restore disposal capacity complement the daily mechanisms that clear the brain: deep sleep, aerobic circulation, and the removal of inputs that add to the load. The engineering problem solved here is delivery, and delivery has been the binding constraint on every attempt to intervene in the aging brain from the outside.
Original published by Longevity.Technology, by Eleanor Garth.